Proliferative Diabetic Retinopathy (PDR) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Proliferative Diabetic Retinopathy (PDR) – Pipeline Review, H2 2016’, provides an overview of the Proliferative Diabetic Retinopathy (PDR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR)

The report reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Proliferative Diabetic Retinopathy (PDR) therapeutics and enlists all their major and minor projects

The report assesses Proliferative Diabetic Retinopathy (PDR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acucela Inc.

Aerie Pharmaceuticals, Inc.

Antisense Therapeutics Limited

Icon Bioscience, Inc.

OcuCure Therapeutics, Inc.

Ohr Pharmaceutical Inc.

PanOptica, Inc.

Ribomic Inc.

ThromboGenics NV

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Proliferative Diabetic Retinopathy (PDR) Overview 6

Therapeutics Development 7

Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview 7

Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies 8

Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies 11

Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development 12

Acucela Inc. 12

Aerie Pharmaceuticals, Inc. 13

Antisense Therapeutics Limited 14

Icon Bioscience, Inc. 15

OcuCure Therapeutics, Inc. 16

Ohr Pharmaceutical Inc. 17

PanOptica, Inc. 18

Ribomic Inc. 19

ThromboGenics NV 20

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

AR-13154 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

atesidorsen sodium - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

cyclosporine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

emixustat hydrochloride - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

OC-10X - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ocriplasmin - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

OLX-302 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

PAN-90806 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

RBM-008 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

squalamine lactate - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects 60

Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones 61

Featured News & Press Releases 61

May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Acucela Inc., H2 2016 12

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 13

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Antisense Therapeutics Limited, H2 2016 14

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Icon Bioscience, Inc., H2 2016 15

Proliferative Diabetic Retinopathy (PDR) – Pipeline by OcuCure Therapeutics, Inc., H2 2016 16

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Ohr Pharmaceutical Inc., H2 2016 17

Proliferative Diabetic Retinopathy (PDR) – Pipeline by PanOptica, Inc., H2 2016 18

Proliferative Diabetic Retinopathy (PDR) – Pipeline by Ribomic Inc., H2 2016 19

Proliferative Diabetic Retinopathy (PDR) – Pipeline by ThromboGenics NV, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Proliferative Diabetic Retinopathy (PDR) – Dormant Projects, H2 2016 60

List of Figures

List of Figures

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Top 10 Targets, H2 2016 22

Number of Products by Stage and Top 10 Targets, H2 2016 22

Number of Products by Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports